This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Managing volatility involves calibrating exposure, diversification, and hedging to stabilize crypto portfolio performance.
25,445 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
A focused $8 million investment could trigger a dramatic move in a biotech stock. Learn how three NDA filings and a d...
When a CEO discloses a sale of 41,600 shares, investors pay attention. This article unpacks the implications, the mec...
As Berkshire Hathaway transitions from Buffett to Greg Abel, Abel makes a bold opening move. This piece explains the ...
Investors are placing massive bets on Eli Lilly’s GLP-1 drugs, but the push for a $1 trillion opportunity faces medic...
When oil surges, mining companies feel the sting long before metals move. This article breaks down how energy costs p...
Memory plays a critical role in AI growth, and micron's data center gross margin has surged to industry-leading level...
The AI stock story is shifting from last year’s heroes to new winners in 2026. This guide explains why the leadership...
When a celebrity moment goes beyond fashion, it becomes a teachable moment for money. This piece breaks down the fina...
Investors are seeing a mining stock flying this week, led by SSR Mining. This piece breaks down the catalysts beyond ...
Shoe Carnival's 2025 earnings season offers clues about margins, online growth, and store results. This guide breaks ...
Divisadero Street Capital Management upped its stake in Dave (DAVE), fueling questions about a potential buying oppor...